Small Cell Neuroendocrine Carcinoma of the Prostate on 18F-DCFPyL and 18F-FDG PET/CT.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
aheadofprint
Résumé
A 51-year-old man with newly diagnosed small cell neuroendocrine carcinoma of the prostate was referred for a staging 18F-DCFPyL PET/CT, which showed a solitary metastasis in the left acetabulum. Subsequent 18F-FDG PET/CT showed intense uptake throughout the prostate as well as extensive avid pelvic and thoracic nodal disease and redemonstration of the left acetabular metastasis. Despite initial metabolic response to treatment, subsequent 18F-FDG PET 8 months later revealed significant progression of nodal disease above and below the diaphragm, as well as multiple new sites of metastases.
Identifiants
pubmed: 38377379
doi: 10.1097/RLU.0000000000005110
pii: 00003072-990000000-00945
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Taher A, Jensen CT, Yedururi S, et al. Imaging of neuroendocrine prostatic carcinoma. Cancers (Basel). 2021;13:5765.
Aggarwal R, Zhang T, Small EJ, et al. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014;12:719–726.
Bilen MA, Akintayo A, Liu Y, et al. Prognostic evaluation of metastatic castration resistant prostate cancer and neuroendocrine prostate cancer with [68Ga]Ga DOTATATE PET-CT. Cancers (Basel). 2022;14:6039.
Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7–18.
Cai J, Xu W, Meng T, et al. Visualization of intermetastatic heterogeneity in mixed neuroendocrine carcinoma–acinar adenocarcinoma of the prostate by 68Ga-PSMA, 68Ga-FAPI, and 18F-FDG PET/CT. Clin Nucl Med. 2023;48:743–745.
Usmani S, Ahmed N, Marafi F, et al. Molecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CT. Clin Nucl Med. 2017;42:410–413.
Parida GK, Tripathy S, Datta Gupta S, et al. Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT over 68Ga-PSMA PET/CT. Clin Nucl Med. 2018;43:248–249.
Spratt DE, Gavane S, Tarlinton L, et al. Utility of FDG-PET in clinical neuroendocrine prostate cancer. Prostate. 2014;74:1153–1159.